Aging Gracefully: MyMD Pharmaceuticals Developing Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals (Nasdaq: MYMD) has provided a dosing update on its Phase 2 clinical trial of lead drug candidate MYMD-1® as a therapy for chronic inflammation associated with sarcopenia and frailty. The company’s share price rose nearly 20% in intra-day trading following the news.

Chris Chapman MD, President, Director, and Chief Medical Officer at MyMD Pharmaceuticals, said, “We are proud of the notable progress that we have made thus far on our first Phase 2 study of MYMD-1…we remain hopeful in MYMD-1’s potential to transform future treatment of sarcopenia/frailty in the aging population.”


MyMD’s trial is an ongoing Phase 2 multi-center double-blind, placebo controlled, randomized study (NCT05283486) to investigate the efficacy, tolerability and pharmacokinetics of MYMD-1 in the treatment of chronic inflammation associated with sarcopenia/frailty inpatients aged 65 years or older.

The study enrolled 30 patients aged 65 years or older. All subjects have officially completed study parameters and have been discharged from the study.

The study’s primary objective is to demonstrate reduction of chronic inflammatory markers in patients treated with MYMD-1® versus placebo.

The study’s Safety Review Committee has confirmed no safety or toxicity issues with the first 30 patients enrolled in the study and has voted to escalate to the final dose level.

It is estimated that 5 to 13% of elderly people between the ages of 60 and 70 are affected by sarcopenia. Currently, there are no FDA approved treatments for chronic inflammation associated with sarcopenia/frailty for those aged 65 years or older.

MyMD’s clinical trial is fully-funded

About MyMD Pharmaceuticals

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. MyMD’s lead clinical candidate, MYMD-1®, is an orally available next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated. MYMD-1®, with its small molecule design, improved safety profile and ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-α inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases. MYMD-1® has demonstrated the potential to slow the aging process and extend healthy lifespan. The company is evaluating MYMD-1® in Phase 2 studies for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications.

MyMD’s second therapeutic candidate is Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times more potent a CB2 agonist (activator) than plant-based CBD. The U.S. Drug Enforcement Administration (DEA)’s scientific review concluded Supera-CBD will not be considered a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations or require scheduling during development. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown to have anti-inflammatory effects. For more information, visit

Share This Article


About the Author

Aging Gracefully: MyMD Pharmaceuticals Developing Therapy for Delaying Aging and Extending Healthy Lifespan

Editor Prism MarketView